Status:
COMPLETED
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Children's Oncology Group
EsPhALL
Conditions:
Leukemia, Pediatric
Eligibility:
All Genders
1-17 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic...
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
- Newly diagnosed Philadelphia chromosome positive Acute Lymphoblastic Leukemia (ALL)
- Age \>1 year and \< less than 18 years old
- Induction chemotherapy ≤ 14 days according to institutional standard of care
- Adequate liver, renal and cardiac function
Exclusion
- Prior treatment with a Oncogene fusion protein (BCR-ABL) inhibitor
- Extramedullary involvement of the testicles
- Active systemic bacterial, fungal or viral infection
- Down syndrome
Key Trial Info
Start Date :
April 13 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2021
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT01460160
Start Date
April 13 2012
End Date
June 1 2021
Last Update
December 8 2021
Active Locations (128)
Enter a location and click search to find clinical trials sorted by distance.
1
University Of Alabama At Birmingham
Birmingham, Alabama, United States, 35233
2
Phoenix Children'S Hospital/Ctr. For Cancer & Blood Ctr.
Phoenix, Arizona, United States, 85016
3
University Of Arkansas For Medical Sciences
Little Rock, Arkansas, United States, 72202
4
Antranik Agop Bedros
Loma Linda, California, United States, 92350